key: cord-0996240-vrtvgye0
authors: Joob, Beuy; Wiwanitkit, Viroj
title: Estimated CD4+ count: Appraisal on cases with COVID-19
date: 2021-09-30
journal: J Res Med Sci
DOI: 10.4103/jrms.jrms_244_20
sha: 209783eec763c5c1e18fe15fb7d32c95f2a1c4f8
doc_id: 996240
cord_uid: vrtvgye0

nan

Dear Editor, COVID-19 infection is an emerging novel coronavirus infection. [1] This new infection started in China in December 2019. Now (March 7, 2020), it already causes health problem in more than 50 countries in all continents except for Antarctica. Clinically, this new infection causes acute febrile illness and severe respiratory distress might occur. [2] [3] [4] Regarding basic laboratory investigation, decreased lymphocyte count is a hematological finding from complete blood count. [2] [3] [4] Nevertheless, there has never reported on its effect of specific lymphocyte subsets. Here, the authors reappraised on clinical data on published data to estimate the CD4 + count in COVID-19. Based on available data on 278 cases with COVID, [2] [3] [4] the authors performed a summative analysis on total lymphocyte count (TLC) and additional estimation of CD4 count based on the mathematical model technique. [5] The referred mathematical model is "CD4 + count = 0.24 × TLC − 5.97." [5] Based on summative analysis, the mean TLC is equal to 840 cells/µL, therefore, the derived estimated CD4+ count is equal to 195.63 cells/µL). Therefore, the low CD4+ count is observed, and this reflects the nature of immunodeficiency in COVID-19 infection. Further studies on immunopathological due to the new infection are recommended.

Nil.

Emerging new coronavirus infection in Wuhan, China: Situation in early 2020

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Absolute lymphocyte count as a surrogate marker for CD4 counts after six months of HAART initiation in a resource-limited setting in India

There are no conflicts of interest.